CELL & GENE CAPACITY UPDATE VIDEOS
The Future Of Lentiviral Vector Innovation And Access
Founded on lentiviral vector design and manufacturing excellence, VBM and the LENTIVERSE™ technology platform provide a full suite of tools to quickly deliver state-of-the-art therapies and develop next-generation products.
Minaris Advanced Therapies Capacity Update October 2025: Cell & Gene Therapy
During this session, we will provide an overview of our capabilities, including our contract testing services, and an update on our current capacity.
Ascend & ABL Inc. Capacity Update October 2025: Cell & Gene Therapy
Operating from state-of-the-art GMP facilities, we provide end-to-end services to commercial, academic, and government clients, spanning process innovation through development, GMP manufacturing, QC testing, to aseptic fill/finish.
Andelyn Biosciences Capacity Update October 2025: Cell & Gene Therapy
A risk-based framework for identity testing of ancillary raw materials in gene therapy is presented, with emphasis on implementation based on product contact, material classification, and manufacturing stage.
Viralgen Capacity Update July 2025: Cell & Gene Therapy
As a leading CDMO in AAV manufacturing, Viralgen facilitates rapid transition to cGMP with a proven platform and an impeccable 100% IND success rate. Discover how Viralgen drives industry progress.
Minaris Advanced Therapies Capacity Update July 2025: Cell & Gene Therapy
With a robust track record of more than 7,500 GMP batches and proven platforms for multiple modalities, Minaris delivers speed, scalability, and reliability to help therapeutic developers bring cures to patients faster.
Excellos Capacity Update July 2025: Cell & Gene Therapy
Excellos leverages its extensive starting material expertise as a key differentiator. Explore how our deep understanding of partner-sourced raw materials, quality control, and supply chain management creates significant value for our clients.
A Concept-To-Commercial Gene Therapy CDMO
The Curator™ adherent platform has been used to manufacture more than 450 Phase 1 and 2 clinical batches, spanning over 17 years and covering a variety of serotypes and indications.
FUJIFILM Diosynth Biotechnologies Capacity Update April 2025: Cell & Gene Therapy
Director of Commercial Development, Serat Ali, describes FDBs' Advanced Therapy capabilities, discusses their global facilities network, and provides a capacity update.
Vinta Bio Capacity Update April 2025: Cell & Gene Therapy
Uncover how an intensified adherent AAV manufacturing process is unlocking high-yield, low-impurity clinical production with over 95% full capsids in a streamlined, compact platform.
Kincell Bio Capacity Update April 2025: Cell & Gene Therapy
Explore how expert CMC strategies and clinical manufacturing experience can lay the groundwork for the successful commercialization of advanced cell therapies.
Capacity Update April 2025: Cell & Gene Therapy
Witness how NYBCe and CCS are transforming cell and gene therapy development with end-to-end CDMO solutions, advanced logistics, and a growing innovation hub in Louisville.
Miltenyi Biotec B.V. & Co. KG Capacity Update April 2025: Cell & Gene Therapy
In this presentation, Shaan Gareeb highlights the capabilities of our Cell Therapy Center of Excellence in San Jose, California, one of five global Miltenyi Bioindustry sites.
Optimization-By-Design: A Critical Factor In Viral Vector Scale Up, Scale Down
Focusing on critical parameters such as cell culture conditions, viral vector yield, and downstream purification strategies, can drive the success of scale-up and scale-down models for AAV production.
SK pharmteco Capacity Update April 2025: Cell & Gene Therapy
Our integrated expertise — from plasmid science to viral vector and cell therapy manufacturing — can accelerate and de-risk the development of your advanced therapies.
Advancing Cell & Gene Therapies To Patients
Discover how we apply our expertise and know-how to efficiently advance your viral vector-based therapeutic through any phase, while enhancing quality and de-risking production.
Forge Biologics, A Member Of Ajinomoto Bio-Pharma Services, Capacity Update January 2025: Cell & Gene Therapy
See how Forge’s dedicated 200,000 sq. ft. facility, proprietary technologies, and specialized services provide expert AAV manufacturing to empower developers from discovery to delivery and every step in between.
Andelyn Biosciences Capacity Update January 2025: Cell & Gene Therapy
Here we introduce the structure and capabilities of our Laboratory Services group, a cornerstone of our commitment to excellence in pharmaceutical development.
Aldevron Capacity Update January 2025: Cell & Gene Therapy
In this session, you will discover how Alchemy technology utilizes a cell-free, enzymatic DNA manufacturing process that accelerates linDNA template production, allowing you to expedite your mRNA research and development pipeline.
Agenda & Presenter Details
Visit our registration pages to see the current agenda and our list of presenting sponsors.
How can we help?
Are you a supplier looking to present at our next event?